A Massachusetts-based %Biotech company is making waves Tuesday morning after the company reportedly received regulatory guidance from the U.K.’s regulatory agency for %AXA1125 as a treatment for long Covid fatigue.

This exciting news have traders bidding up shares of %AxcellaHealth ($AXLA) during Tuesday’s premarket action as shares are currently bid at $0.66/share (+53.49% implied open for sellers) at the time of writing. This move will be a strong continuation of the success this stock has had over the last few weeks.

Axcella Health Inc a biotechnology company focused on treating complex diseases and improve health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company's pipeline includes lead therapeutic candidates, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125 for non-alcoholic steatohepatitis.

Strong Premarket Bid For This Micro Cap

{{articledata.title}}

{{articledata.title}}

More from @{{articledata.company.replace(" ", "") }}

Distribution Reinvented

Latest Articles

Contacts